- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Marksans Pharma Ltd (MARK)
The Marksans Pharma Ltd share price today is 260.80, view NSE MARK stock exchange data. Track the latest Marksans Pharma Ltd share price with real-time updates on MARK stock performance including market cap, day range, 52-week range and dividend yield. Access MARK charts, earnings dates and analyst estimates to support your investment decisions.
260.80
-3.65(-1.38%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
257.50
269.20
52 wk Range
155.00
278.80
MARK is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
257.50269.20
52 wk Range
155.00278.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MARK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
266.00
Upside
+1.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 266.00
(+1.99% Upside)
Earnings
Latest Release
26-05-2026
EPS / Forecast
3.25 / --
Revenue / Forecast
8.58B / --
Compare MARK to Peers and Sector
Metrics to compare | MARK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMARKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.7x | 28.9x | −0.4x | |
PEG Ratio | 2.93 | 0.25 | 0.00 | |
Price/Book | 4.0x | 3.2x | 2.6x | |
Price / LTM Sales | 4.1x | 3.7x | 3.0x | |
Upside (Analyst Target) | 9.7% | 6.0% | 49.1% | |
Fair Value Upside | Unlock | 2.3% | 6.3% | Unlock |
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Marksans Pharma Ltd (MARK) Share Price Today?
The Marksans Pharma Ltd share price today is 260.80.
What is the current Marksans Pharma Ltd (MARK) share price and day range?
As of 06-07-2026, the Marksans Pharma Ltd share price is 260.80, with a previous close of 264.45. The share price has ranged from 257.50 to 269.20 today, while the 52-week range spans from 155.00 to 278.80.
What Is the Marksans Pharma Ltd Market Cap?
As of today, Marksans Pharma Ltd market cap is 117.80B.
Does Marksans Pharma Ltd Pay Dividends? What's The Current Dividend Yield?
The Marksans Pharma Ltd dividend yield is 0.3%.
What Is the Marksans Pharma Ltd (MARK) Share Price Target?
The average 12-month share price target for Marksans Pharma Ltd is 266.00, with a high estimate of 298 and a low estimate of 210. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +1.99% Upside potential.
What Is Marksans Pharma Ltd's Earnings Per Share (TTM)?
The Marksans Pharma Ltd EPS (TTM) is 9.22.
When Is the Next Marksans Pharma Ltd Earnings Date?
Marksans Pharma Ltd will release its next earnings report on 06-08-2026.
From a Technical Analysis Perspective, Is MARK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does Marksans Pharma Ltd Trade On?
Marksans Pharma Ltd is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Marksans Pharma Ltd?
The stock symbol for Marksans Pharma Ltd is "MARK."
How Many Times Has Marksans Pharma Ltd Stock Split?
Marksans Pharma Ltd has split 1 times.
How Many Employees Does Marksans Pharma Ltd Have?
Marksans Pharma Ltd has 1840 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.